التفاصيل البيبلوغرافية
| العنوان: |
A High Proliferative Index of Recurrent Melanoma Is Associated with Worse Survival. |
| المؤلفون: |
Tu, Ting J., Ma, Michelle W., Monni, Stefano, Rose, Amy E., Yee, Herman, Darvishian, Farbod, Polsky, David, Berman, Russell S., Shapiro, Richard L., Pavlick, Anna C., Mazumdar, Madhu, Osman, Iman |
| المصدر: |
Oncology; 2011, Vol. 80 Issue 3/4, p181-187, 7p, 1 Color Photograph, 4 Charts |
| مصطلحات موضوعية: |
MELANOMA, PROGNOSIS, ANTIGENS, TUMORS, NEUROENDOCRINE tumors |
| مستخلص: |
Objective: Previous melanoma studies evaluating prognostic factors of survival at recurrence have focused on primary tumor characteristics and clinical variables at first recurrence. We examined the prognostic relevance of recurrent tumor proliferation. Methods: 114 melanoma patients with available recurrent tissues who were prospectively enrolled at New York University Medical Center were studied. Standard of care prognostic variables (e.g. stage at initial diagnosis and lactate dehydrogenase level) and recurrent tissue expression of proliferative marker Ki-67 were evaluated for their association with overall survival. Results: High Ki-67 expression was observed in 57 (50%) of the 114 recurrent melanomas. On univariate analysis, the median overall survival of patients whose recurrent tumors overexpressed Ki-67 was significantly shorter than that of patients whose recurrent tumors had low Ki-67 expression (3.6 vs. 9.5 years, p = 0.03). On multivariate analysis, a high proliferative index of the recurrent melanoma remained an independent predictor of worse overall survival, controlling for stage at initial diagnosis, disease-free survival, and stage at first recurrence [HR = 2.09 (95% CI 1.24-3.54), p = 0.006]. Conclusions: Our results demonstrate the prognostic relevance of tumor proliferation in recurrent melanoma patients. Data also support restratification of risk assessment upon recurrence that considers tumor biology in addition to clinical variables evaluated as part of the standard of care. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncology is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
